For­mer Prometheus ex­ecs raise $400M for pre­ci­sion im­munol­o­gy start­up: 'The band is back to­geth­er'

Af­ter sell­ing his last com­pa­ny to Mer­ck for $10.8 bil­lion in June, Mark McKen­na couldn’t shake the feel­ing that he’d left the job un­fin­ished.

On Thurs­day, his new start­up Mi­rador Ther­a­peu­tics launched with a mas­sive $400 mil­lion Se­ries A, by far the biggest sin­gle pri­vate fund­ing round of the year in biotech. Led by ARCH Ven­ture Part­ners, more than a dozen oth­er in­vestors chipped in, in­clud­ing Or­biMed, Fair­mount, and Sanofi Ven­tures.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER